Epidemiology, surveillance and control of infectious diseases in the European overseas countries and territories, 2011.

The 25 European overseas countries and territories (OCTs) are closely associated with the European Union (EU) through the four related UE Member States: Denmark, France, the Netherlands and the United Kingdom. In 2008 and 2009, these four EU Member States, in association with the European Centre for Disease Prevention and Control (ECDC), reviewed the OCTs' needs, with the objectives of documenting their capacity to prevent and respond to infectious diseases outbreaks, and identifying deficiencies. This Euroroundup is based on the review's main findings, and presents an overview of the OCTs' geography and epidemiology, briefly introduces the legal basis on which they are linked to the EU and describes the surveillance and infectious disease response systems. As a result of their diversity the OCTs have heterogeneous epidemiological profiles. A common factor, however, is that the main burden of disease is non-communicable. Nevertheless, OCTs remain vulnerable to infectious diseases outbreaks. Their capacity for surveillance, early detection and response to such outbreaks is generally limited, with laboratory capacity issues and lack of human resources. Avenues for capacity strengthening should be explored by the OCTs and the related EU Member States, in collaboration with ECDC and regional public health networks where these exist.

The influenza A(H5N1) epidemic at six and a half years: 500 notified human cases and more to come.

Since November 2003, the epidemic intelligence team at the French Institut de Veille Sanitaire has been gathering data on influenza A(H5N1) circulation in poultry and on human cases worldwide. As Indonesia notifies the world's 500th case to the World Health Organization, we discuss the epidemiological situation and trends of A(H5N1) influenza. Although the overall number of cases reported worldwide has decreased, influenza A(H5N1) continues to circulate intensely in some countries and more cases are to be expected, especially in Egypt and Indonesia.

First two autochthonous dengue virus infections in metropolitan France, September 2010.

In September 2010, two cases of autochthonous dengue fever were diagnosed in metropolitan France for the first time. The cases occurring in Nice, southeast France, where Aedes albopictus is established, are evidence of dengue virus circulation in this area. This local transmission of dengue calls for further enhanced surveillance, active case finding and vector control measures to reduce the spread of the virus and the risk of an epidemic.

The 2009 pandemic H1N1 influenza and indigenous populations of the Americas and the Pacific.

There are few structured data available to assess the risks associated with pandemic influenza A(H1N1)v infection according to ethnic groups. In countries of the Americas and the Pacific where these data are available, the attack rates are higher in indigenous populations, who also appear to be at approximately three to six-fold higher risk of developing severe disease and of dying. These observations may be associated with documented risk factors for severe disease and death associated with pandemic H1N1 influenza infection (especially the generally higher prevalence of diabetes, obesity, asthma, chronic obstructive pulmonary disease and pregnancy in indigenous populations). More speculative factors include those associated with the risk of infection (e.g. family size, crowding and poverty), differences in access to health services and, perhaps, genetic factors. Whatever the causes, this increased vulnerability of indigenous populations justify specific immediate actions in the control of the current pandemic including primary prevention (intensified hygiene promotion, chemoprophylaxis and vaccination) and secondary prevention (improved access to services and early treatment following symptoms onset) of severe pandemic H1N1 influenza infection.

[Chagas disease in France: estimated number of infected persons and cardiac diseases in 2009, by risk groups]. / Maladie de Chagas en France: estimation du nombre de personnes infectées et d'atteintes cardiaques en 2009, selon les groupes & risque.

An estimation of the number of Trypanosoma cruzi infected individuals and expected number of Chagasic cardiomyopathies in France (excluding French Guyana) was conducted in June, 2009 by InVS. Different risk groups were identified: Latino-Americans (LA) from endemic area (naturalized, legal and illegal migrants, adopted children), children born from LA's mother, French Guyanese living in Metropolitan France, expatriated and travellers from endemic countries. Prevalence rates by country of origin were applied to official data on risk populations obtained from the International Adoption Agency, Tourism Direction and French ministries (Finances, Foreign Affairs and Migrations). Around 157,000 individuals were potentially exposed. It is estimated than 1,464 [895-2,619] are infected by T. cruzi, of which 63 to 555 may evolve towards a chronic cardiomyopathy. This figure is within the range of earlier estimations of InVS and Guerri-Guttenberg. Taking into account illegal immigrants, the expected number of infected individuals in France should increase greatly this estimation.

[Evaluation of the pertinence of international courses on human African trypanosomiasis]. / Evaluation de la pertinence du cours international sur les trypanosomoses humaines africaines.

The goal of this study was to evaluate the adequacy and relevance of a training course on Human African Trypanosomiasis, targeted to reach support and coordination staff in charge of activities being carried out in related prevention and control programmes. A questionnaire was emailed to the four course organisers and the 65 participants. The response rate among the participants was 41%. The training needs expressed covered issues such as treatment, diagnostic and epidemiological techniques, improved knowledge of the disease, and control planning. The lectures given were adapted for participants' professional activities. At the time of the evaluation (one to three years after the course) 67% of the participants had begun implementing the knowledge they had acquired and applying it to their practice, particularly in the area of programme planning. The analysis of the questionnaire's results pointed to the sections of the course that would benefit from modifications, such as the need for the development of lessons and modules in the areas of patient management and planning for future training sessions.

Measles outbreaks in the Mozambican refugee camps in Malawi: the continued need for an effective vaccine.

Between November 1988 and January 1989, measles outbreaks occurred in 11 Mozambican refugee camps in Malawi with five camps principally affected. A total of 1214 cases were reported. Despite the reduction of the age of measles vaccination to six months in 1987, attack rates were highest in children aged 6-9 months (10-26%); rates were also high in the 0-5 month age group (3-21%). The case-fatality rate was high among children less than five years old (15-21%). Children were being inappropriately vaccinated, either being vaccinated at less than six months of age (2-29%) or failing to receive a second dose if vaccinated at six months (0-25%). With vaccine coverage between 66-87%, vaccine efficacy in children less than five years old was estimated to be more than 90% in the camps principally affected. Reduction of the age of vaccination leads to logistical problems in vaccine delivery in refugee situations. These outbreaks again indicate the need to improve vaccine coverage with the existing Schwarz vaccine, and also highlight the urgent need for an effective single dose measles vaccine for children less than nine months of age.

Biological data and clinical symptoms as predictors of astrogliosis and neurodegeneration in patients with second-stage Trypanosoma brucei gambiense sleeping sickness.

Concentrations of glial fibrillary acidic protein (GFAp) and light subunit neurofilament protein (NFL) in cerebrospinal fluid (CSF) were measured in patients with second-stage Trypanosoma brucei gambiense sleeping sickness. Correlations between GFAp and NFL in CSF as markers for astrogliosis and neurodegeneration, and clinical and biological data were investigated. Abnormal levels of GFAp and NFL were significantly associated with increasing CSF cell number and protein concentration, and with the absence of lymph nodes or the absence of trypanosomes in lymph node aspirate. A significant association was found between abnormal NFL and presence of trypanosomes in CSF, abnormal limb movements, difficulties in gait and coordination, and low Karnofsky index. By multivariate analysis, it was shown that increasing CSF cell number, increasing CSF protein concentration, and the absence of lymph nodes or the absence of trypanosomes in the lymph node aspirate were the best predictors for astrogliosis and neurodegeneration among the variables tested. These results demonstrate the importance of CSF cell count and protein determination in assessment of the severity of central nervous system involvement and reinforces the importance of laboratory diagnosis to assess the stage of the disease. The clinical symptoms studied were less useful in predicting astrogliosis or neurodegeneration.

B-mode-guided vector-A-mode versus A-mode biometry to determine axial length and intraocular lens power.

PURPOSE: To compare prospectively the reproducibility and accuracy of B-mode-guided biometry with those of A-scan biometry using a conventional A-mode probe to calculate intraocular lens (IOL) power. SETTING: Department of Ophthalmology, Hôtel-Dieu de Paris, France. METHODS: The axial length (AL) in 87 eyes of 72 candidates for cataract surgery was determined by B-mode-guided vector-A-mode and A-mode biometry using an Ophthascan S Ultrasound imager. Patients were assigned to one of two groups based on the B-mode biometry: nonmyopic (AL < 24.5 mm; n = 54) or myopic (AL > 24.5 mm; n = 33). Postoperative refractive results were compared with attempted values. RESULTS: Mean AL variance was significantly greater when using the A-mode than the B-mode: 0.157 mm +/- 0.260 (SD) versus 0.015 +/- 0.018 mm in the myopic group (P < .001) and 0.024 +/- 0.024 +/- 0.045 versus 0.009 +/- 0.011 mm in the nonmyopic group (P < .001). More eyes having B-mode biometry achieved a final refraction within +/- 0.50 diopter (D) of the attempted refraction (63 and 43%, respectively; P < .05). No deviation greater than 1.60 D was observed with the B-mode in the myopic or nonmyopic group. Three cases with a such a deviation (up to 2.24 D) would have been observed had A-mode-based biometry been chosen for the IOL power calculation. In the myopic group, attempted postoperative refraction was within +/- 0.50 D in 78% of eyes having B-mode biometry compared with 65% having A-mode. This difference was not statistically significant. CONCLUSION> These results suggest that the reproducibility and accuracy of AL measurements are significantly better with B-mode-guided A-mode biometry than with A-mode biometry in myopic and nonmyopic eyes.

[Resistance of Vibrio cholerae 0:1 to the 0/129 compound and multiresistance to antibiotics]. / Résistance de Vibrio cholerae O:1 au composé O/129 et multirésistance aux antibiotiques.

The authors present a study of the in vitro susceptibility to O/129 compound and usual antibiotics of 29 strains of V. cholerae O:1 biotype El Tor isolated during epidemics in miscellaneous countries over the world from 1982 to 1991. Several identical isolates from the same epidemic are represented by one strain. Susceptibility testing by diffusion method and MICs by agar dilution method are used. The data show that the resistance to O/129 compound is often associated with the resistance to usual antibiotics such as trimethoprim, sulphonamides, chloramphenicol, ampicillin and tetracycline. This resistance to the vibrostatic compound leads to a double problem of diagnosis and therapy. The nitrofuranes derivatives and tiliquinol-tilbroquinol association, an intestinal antiseptic, are the most active antimicrobial agents as well on the strains O/129 sensitive as on the strains O/129 resistant.

[Therapeutic failure of melarsoprol among patients treated for late stage T.b. gambiense human African trypanosomiasis in Uganda]. / Echecs thérapeutiques du mélarsoprol parmi des patients traités au stade tardif de trypanosomose humaine africaine à T. b. gambiense en Ouganda.

The failure rate of melarsoprol after treatment of late stage cases of Human African Trypanosomiasis (HAT) is usually under 7%, even though the drug has been used for such treatment over the past 50 years. We report a melarsoprol treatment failure rate of 26.9% among 428 patients treated in Northern Uganda. Whatever its origin, this observation, the first documented in a HAT focus, is alarming, particularly since no second line trypanocidal drug is actually available for the treatment of late stage HAT. We believe that the current worrisome situation of HAT in several African countries and the risk of emergence of other foci of resistance, argue in favour of a greater attention on the part of the scientific community and the pharmaceutical companies being paid to this problem.

[Trypanosomiasis from Trypanosoma brucei gambiense in the center of north-west Uganda. Evaluation of 5 years of control (1987-1991)]. / La trypanosomiase a Trypanosoma brucei gambiense dans le foyer du nord-ouest de l'Ouganda. Bilan de 5 années de lutte (1987-1991).

In Uganda, a case-finding and treatment programme has been implemented by Médecine Sans Frontières (MSF) and the Ministry of Health in the North of West-Nile province. Data collected in the hospital of Moyo from January 1987 to June 1991 were analyzed. Forty eight hundred and twenty two cases of trypanosomiasis due to T. B. gambiense has been recorded. Cumulative incidence rate for this period was 5.6%. Passive and active case-finding strategies were used, both based on Card Agglutination Test (CATT) as screening tool, followed by parasitological examinations. The mobile teams identified 1906 of the 4,822 cases (39.5%). Case fatality rate was 2.6%. This study confirmed the association between social and political disruptions, large movements of population and extension of trypanosomiasis. Active case-finding seems to quickly reduce disease prevalence in hyper-endemic areas. An integrated programme is then necessary to control sleeping sickness transmission.

[Chagas disease (American trypanosomiasis) in France]. / La maladie de Chagas (ou trypanosomose américaine) en France.

Chagas disease is an anthropozoonotic infection caused by Trypanosoma cruzi, transmitted by a hematophagous triatomine insect vector belonging to the Reduviidae family, while taking a blood meal. There is a large reservoir of wild and domestic mammals. Human contamination may come via vectorial, transplacental, and digestive routes, blood transfusion, organ or tissue transplantation, and by accident. The disease has two phases. The acute phase, oligosymptomatic, is frequently undiagnosed. It is followed by a chronic phase. Most of the infected patients remain asymptomatic all life-long. But 10 or 25 years later, one third of infected patients present with cardiac or digestive complications. Chagas disease is endemic in Latin America, from Mexico to Argentina. In French Guyana, the prevalence of the infection was estimated at 0.25% and 0.5% (from 500 to 1000 infected patients) on blood samples collected from 1992 to 1998. In 2000 and 2009, 192 cases were diagnosed. In this district, there is no established domestic vector and the transmission risk is low. The vector is very easily found in forest habitats and even in the peridomestic persistent forest, with an infection rate of 46 to 86%. Vectorial eradication is impossible. Fighting against Chagas disease in French Guyana relies more on individual protection, control of blood transfusion, prevention of mother-to-child transmission, diagnosis, and treatment of infected patients than on vectorial control.

[Malaria in France: Mainland and territories]. / Le paludisme en France : métropole et outre-mer.

Malaria, which was eliminated first from Metropolitan France (mainland and Corsica), then in the French West Indies and the Reunion Island during the 20(th) century, remains endemic in two French territories: French Guiana and the Indian Ocean Mayotte island. Despite differences in the dominating plasmodial species and epidemiological patterns, these two territories have achieved marked quantitative improvements (in the reported number of cases and severe cases) thanks to efforts undertaken over the past decade. The situation, however, remains a concern from a qualitative standpoint with the emergence of resistance to antimalarial drugs and logistical and administrative issues which hinder access to treatment. Although malaria was eradicated in Metropolitan France half a century ago, competent vectors remain present in part or all of these territories and can give rise to limited outbreaks.